AnaptysBio (NASDAQ:ANAB) Lowered to "Neutral" Rating by BTIG Research

AnaptysBio (NASDAQ:ANAB - Get Free Report) was downgraded by equities researchers at BTIG Research from a "buy" rating to a "neutral" rating in a report released on Monday, MarketBeat Ratings reports.

ANAB has been the topic of several other research reports. UBS Group increased their target price on AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. HC Wainwright cut their target price on AnaptysBio from $55.00 to $52.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Guggenheim upped their price target on AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a report on Monday, October 21st. Truist Financial raised their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a report on Thursday, August 15th. Finally, Wedbush restated an "outperform" rating and issued a $42.00 target price on shares of AnaptysBio in a report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $54.64.

AnaptysBio Stock Performance

Shares of AnaptysBio stock traded down $0.58 during trading hours on Monday, reaching $24.38. 1,073,906 shares of the company were exchanged, compared to its average volume of 357,658. The firm has a market cap of $741.88 million, a PE ratio of -3.82 and a beta of -0.24. AnaptysBio has a 1 year low of $14.70 and a 1 year high of $41.31. The stock's fifty day moving average is $28.13 and its 200 day moving average is $29.74.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.58. The company had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Research analysts expect that AnaptysBio will post -6.02 earnings per share for the current year.

Insider Transactions at AnaptysBio

In other news, insider Paul F. Lizzul sold 1,500 shares of the firm's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This trade represents a 8.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric J. Loumeau sold 8,720 shares of the business's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.82, for a total transaction of $347,230.40. Following the transaction, the insider now owns 7,020 shares in the company, valued at approximately $279,536.40. This trade represents a 55.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,440 shares of company stock worth $892,936. Company insiders own 33.70% of the company's stock.

Institutional Investors Weigh In On AnaptysBio

A number of institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in shares of AnaptysBio by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company's stock worth $745,000 after purchasing an additional 525 shares during the period. Algert Global LLC boosted its holdings in AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company's stock worth $255,000 after buying an additional 1,078 shares in the last quarter. nVerses Capital LLC boosted its holdings in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock worth $54,000 after buying an additional 1,400 shares in the last quarter. Values First Advisors Inc. acquired a new position in AnaptysBio during the third quarter worth about $49,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock valued at $195,000 after buying an additional 2,600 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.